U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C44H50N4O2
Molecular Weight 666.8934
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 2
Charge 2

SHOW SMILES / InChI
Structure of ALCURONIUM

SMILES

[H][C@]12C[C@]3([H])C4=CN5C6=CC=CC=C6[C@]78CC[N@@+]9(CC=C)C\C(=C\CO)[C@]([H])(C[C@@]79[H])C(=CN%10C%11=CC=CC=C%11[C@@]1(CC[N@@+]2(CC=C)C\C3=C\CO)[C@]4%10[H])[C@]58[H]

InChI

InChIKey=MUQUYTSLDVKIOF-CHJKCJHBSA-N
InChI=1S/C44H50N4O2/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2/q+2/b29-13-,30-14-,33-25-,34-26-/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17722904 | https://goo.gl/8mllN4 | https://www.drugs.com/international/alcuronium-chloride.html

Alcuronium (diallylnortoxiferine) is a semi-synthetic substance prepared from C-toxiferine I a bis-quaternary alkaloid obtained from Strychnos toxifera. Alcuronium is a neuromuscular blocking (NMB) agent, alternatively referred to as a skeletal muscle relaxant. Alcuronium is used for endotracheal intubation and to produce muscle relaxation in general anesthesia during surgical procedures. The pharmacological action of alcuronium is readily reversed by neostigmine, and it produced little histamine release. The major disadvantage of alcuronium is that it elicits a vagolytic effect produced by a selective atropine-like blockade of cardiac muscarinic receptors.

Originator

Curator's Comment: # F. Hoffmann-La Roche & Co., A.-G.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Alloferin

Approved Use

Indications. Alcuronium (Cl) is primarily indicated in conditions like Adjunct to anesthesia, Neuromuscular blockade.
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Adult: Initially, 150-250 mcg/kg; additional doses of 30 mcg/kg may be given as needed.
Route of Administration: Intravenous
Left atria were mounted in organ baths containing 20 ml of oxygenated Tyrode’s solution. The preparations were preloaded with 5 millinewton and electrically stimulated via platinum contact electrodes at 3 Hz with rectangular pulses of 5-ms duration. The voltage was 1.5-fold over the threshold of excitation amounting to about 2 V. Contraction force (CF) was recorded isometrically. After an equilibration period of 60 min, a cumulative concentration/effect curve for the negative inotropic action of the agonist under study was recorded. Each agonist concentration was applied for 10 min, a period sufficient to obtain equilibrium effects. Contraction force was expressed as the percentage of the value found at the end of the equilibration period. The agonist was removed from the organ bath over a period of 30 min by replacing the Tyrode’s solution with fresh solution every 10 min. Thereafter, the preparation was preincubated with the Alcuronium for 60 min before another agonist concentration/effect curve was measured in the presence of the Alcuronium. Contraction force was expressed as the percentage of the value at the end of the preincubation period with the Alcuronium. The agonist was washed out using Tyrode’s solution still containing the Alcuronium in the concentration as before. After 30 min of washout, the concentration of the Alcuronium was increased, and, after a preincubation phase of 60 min, another concentration/effect curve of the agonist was measured.
Name Type Language
ALCURONIUM
MI   WHO-DD  
Common Name English
TOXIFERINE I, 4,4'-DIDEMETHYL-4,4'-DI-2-PROPENYL-
Common Name English
DIALLYLNORTOXIFERINE
Common Name English
ALCURONIUM [MI]
Common Name English
ALCURONIUM CATION
Common Name English
ALCURONIUM ION
Common Name English
N,N'-DIALLYLNORTOXIFERINIUM
Common Name English
Alcuronium [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC M03AA01
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
WHO-VATC QM03AA01
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
Code System Code Type Description
RXCUI
460
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY RxNorm
MESH
D000443
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
PUBCHEM
21158560
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
WIKIPEDIA
Alcuronium
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
DRUG BANK
DB13648
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
CAS
23214-96-2
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
MERCK INDEX
m1484
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
109
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
SMS_ID
100000077989
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
EVMPD
SUB12766MIG
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
CHEBI
55313
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID8048234
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY
FDA UNII
S8U3J5W06N
Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023
PRIMARY